Alcon posts steady growth in Vision Care and Surgical, with new drug and therapy launches ahead but execution risks persist.

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Alcon’s IFRS operating margin improved dramatically from 15.1% in Q1 2024 to 19.1% in Q1 2025. The following bridge chart explains the components of this improvement: ...

The company reported $1.4 billion in cash and cash equivalents on its balance sheet, with total debt of $4.7 billion. Capital expenditures totaled $106 million in the quarter, primarily for ...

Alcon Inc. has received its first Food and Drug Administration approval since its spinoff from Swiss medical giant Novartis ...

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Turkey Contact Lens Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering.

Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Turkey Contact Lens Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering. Turkey's ...